[A20-86] Sofosbuvir/velpatasvir (chronic hepatitis C in children and adolescents) - Benefit assessment according to §35a Social Code Book V
Last updated 04.01.2021
Project no.:
A20-86
Commission:
Commission awarded on 22.09.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
| Children and adolescents aged 6 to < 18 years (body weight of at least 17kg) with chronic hepatitis C |
Result of dossier assessment:
| Patients aged 6 to 11 years with genotype 1 or 3: hint of non-quantifiable added benefit. Older patients and other genotypes: added benefit not proven |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A16-48 | Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V | Commission completed |
| A22-26 | Sofosbuvir/velpatasvir (chronic hepatitis C in children 3 to < 6 years of age) - Benefit assessment according to §35a Social Code Book V | Commission completed |